Sharon Marsh1. 1. Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, 5000 rue Bélanger, Montreal, Quebec, Canada. smarsh@pgx.ca
Abstract
OBJECTIVES: Taxane (paclitaxel or docetaxel) and platinum (cisplatin or carboplatin) chemotherapy is commonly used in the treatment of ovarian cancer. Despite an initial high response to therapy, the 5-year survival rate remains low. The identification of pharmacogenomic markers to identify patients unlikely to respond or at risk for severe toxicity will assist in the goal of individualizing ovarian cancer treatment. MATERIALS AND METHODS: Most studies have assessed single nucleotide polymorphisms from genes involved in the pharmacokinetics and pharmacodynamics of the drugs. RESULTS: Unfortunately, most markers identified have not been replicated in subsequent studies. CONCLUSIONS: Other mechanisms of variability, including epigenetic control of gene expression and copy number variation, may play important roles. In addition, nongenetic influences such as concurrent medications, and physiological and environmental factors could also affect individual responses to taxane and platinum therapy.
OBJECTIVES:Taxane (paclitaxel or docetaxel) and platinum (cisplatin or carboplatin) chemotherapy is commonly used in the treatment of ovarian cancer. Despite an initial high response to therapy, the 5-year survival rate remains low. The identification of pharmacogenomic markers to identify patients unlikely to respond or at risk for severe toxicity will assist in the goal of individualizing ovarian cancer treatment. MATERIALS AND METHODS: Most studies have assessed single nucleotide polymorphisms from genes involved in the pharmacokinetics and pharmacodynamics of the drugs. RESULTS: Unfortunately, most markers identified have not been replicated in subsequent studies. CONCLUSIONS: Other mechanisms of variability, including epigenetic control of gene expression and copy number variation, may play important roles. In addition, nongenetic influences such as concurrent medications, and physiological and environmental factors could also affect individual responses to taxane and platinum therapy.
Authors: Peter H O'Donnell; Shaheen Alanee; Kelly L Stratton; Ilana R Garcia-Grossman; Hongyuan Cao; Irina Ostrovnaya; Elizabeth R Plimack; Christopher Manschreck; Cory Ganshert; Norm D Smith; Gary D Steinberg; Joseph Vijai; Kenneth Offit; Walter M Stadler; Dean F Bajorin Journal: Clin Genitourin Cancer Date: 2016-03-10 Impact factor: 2.872
Authors: Martha R C Bhattacharya; Josiah Gerdts; Sarah A Naylor; Emily X Royse; Sarah Y Ebstein; Yo Sasaki; Jeffrey Milbrandt; Aaron DiAntonio Journal: J Neurosci Date: 2012-04-11 Impact factor: 6.167
Authors: Jennifer Permuth-Wey; William J Fulp; Brett M Reid; Zhihua Chen; Christina Georgeades; Jin Q Cheng; Anthony Magliocco; Dung-Tsa Chen; Johnathan M Lancaster Journal: Int J Cancer Date: 2015-08-28 Impact factor: 7.396
Authors: Alexandria M Haslehurst; Madhuri Koti; Moyez Dharsee; Paulo Nuin; Ken Evans; Joseph Geraci; Timothy Childs; Jian Chen; Jieran Li; Johanne Weberpals; Scott Davey; Jeremy Squire; Paul C Park; Harriet Feilotter Journal: BMC Cancer Date: 2012-03-19 Impact factor: 4.430